Stock Events

Stock Events

Patrys Limited 

$0.060000
0
+$0.00+0% Thursday 20:00

Statistics

Day High
0.06
Day Low
0.06
52W High
0.06
52W Low
0.04
Volume
20,000
Avg. Volume
0
Mkt Cap
20.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-362.15%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
530,739.69Revenue
-1.92MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Macrogenics
MGNX
Mkt Cap263.08M
MacroGenics develops monoclonal antibody-based therapeutics for the treatment of cancer, competing in the same biotechnological sector as Patrys.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics focuses on allogeneic CAR T therapies for cancers, competing in the next-generation cancer therapy space.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a significant portfolio in innovative cancer therapies, including CAR T-cell products.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cellular therapy space for cancer, similar to Patrys' therapeutic focus.

About

Based in Melbourne, Australia, Patrys Limited and its subsidiaries specialize in developing and commercializing advanced antibody technologies for cancer treatment. Their leading therapeutic, Deoxymab 3E10, is a distinctive DNA damage-repair antibody capable of penetrating cell nuclei. The company's pipeline also includes PAT-DX1, an antibody fragment specifically designed to target both primary and secondary brain cancers. Furthermore, Patrys is progressing PAT-DX3, a full-sized antibody that shares PAT-DX1's DNA-binding and DNA damage repair blocking properties, currently being evaluated for its tissue distribution and pharmacokinetic profile. Another promising development is PAT-DX1-NP, a product leveraging the targeted delivery of therapeutic payload-carrying nanoparticles directly into cancer cells. Patrys Limited was established in 2006.
Show more...
CEO
Dr. Samantha South GAICD, MBA, Ph.D.
Employees
15
Country
Australia
ISIN
AU000000PAB9

Listings

OTC Link
US
PABAF
AU
AU
PAB.AU

0 Comments

Share your thoughts

FAQ

What is Patrys Limited stock price today?▼
The current price of PABAF is $0.06 USD — it has increased by +0% in the past 24 hours. Watch Patrys Limited stock price performance more closely on the chart.
What is Patrys Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Patrys Limited stocks are traded under the ticker PABAF.
What is Patrys Limited market cap?▼
Today Patrys Limited has the market capitalization of 20.44M
What is Patrys Limited revenue for the last year?▼
Patrys Limited revenue for the last year amounts to 530,739.69 USD.
What is Patrys Limited net income for the last year?▼
PABAF net income for the last year is -1.92M USD.
How many employees does Patrys Limited have?▼
As of September 04, 2026, the company has 15 employees.
In which sector is Patrys Limited located?▼
Patrys Limited operates in the Other sector.
When did Patrys Limited complete a stock split?▼
The last stock split for Patrys Limited was on October 13, 2025 with a ratio of 1:15.
Where is Patrys Limited headquartered?▼
Patrys Limited is headquartered in Nedlands, Australia.